26
Participants
Start Date
February 28, 2003
Primary Completion Date
February 28, 2007
Study Completion Date
January 31, 2008
fosbretabulin disodium
Combretastatin A4 phosphate IV over 10 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 courses beyond documentation of the CR.
Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh
Josephine Ford Cancer Center at Henry Ford Hospital, Detroit
Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center, Cleveland
National Cancer Institute (NCI)
NIH
Case Comprehensive Cancer Center
OTHER